SCHEMBL3479602

SCHEMBL3479602

CN1CCN(c2ccc(Cl)c(Cl)c2)c2ccc(-n3nc4ccccn4c3=O)cc2C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 6/20 0.47
SLC6A2 P23975 5/20 0.47
SLC6A3 Q01959 3/20 0.47
KCNH2 Q12809 5/20 0.39
DRD2 P14416 3/20 0.39
DRD3 P35462 2/20 0.39
GPR139 Q6DWJ6 1/20 0.36
GAA P10253 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CYP2D6 P10635 3/20 0.36
CYP2C19 P33261 2/20 0.36
SIGMAR1 Q99720 4/20 0.35
ALDH1A1 P00352 3/20 0.35
LMNA P02545 2/20 0.35
KDM4E B2RXH2 2/20 0.35
HTR1A P08908 2/20 0.35
HPGD P15428 2/20 0.35
HTR2A P28223 2/20 0.35
HSD17B10 Q99714 2/20 0.35
ABCB11 O95342 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3480000 0.90 SLC6A4 (0.55) SLC6A4SLC6A2SLC6A3KCNH2DRD2
SCHEMBL3479704 0.89 SLC6A4 (0.46) SLC6A4SLC6A2SLC6A3KCNH2DRD2
SCHEMBL3479759 0.88 SLC6A2 (0.44) SLC6A4SLC6A2SLC6A3DRD2GAA
SCHEMBL3479670 0.87 SLC6A4 (0.45) SLC6A4SLC6A2SLC6A3KCNH2DRD2
SCHEMBL3480094 0.87 SLC6A4 (0.44) SLC6A4SLC6A2SLC6A3KCNH2DRD2
SCHEMBL3479545 0.86 SLC6A4 (0.43) SLC6A4SLC6A2SLC6A3KCNH2DRD2
SCHEMBL3227717 0.86 SLC6A4 (0.44) SLC6A4SLC6A2SLC6A3KCNH2DRD2
SCHEMBL3228837 0.84 SLC6A4 (0.44) SLC6A4SLC6A2SLC6A3KCNH2DRD2
SCHEMBL3479673 0.80 SLC6A2 (0.47) SLC6A4SLC6A2SLC6A3KCNH2DRD2
SCHEMBL3231196 0.77 SLC6A2 (0.47) SLC6A4SLC6A2SLC6A3KCNH2DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096546-B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-08-04 US disclosed
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ADRA1B, ADRB1, ADRA1D SLC6A4 40/4885SLC6A2 28/4885SLC6A3 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.